News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
13,992 Results
Type
Article (760)
Company Profile (19)
Press Release (13213)
Section
Business (4768)
Career Advice (16)
Deals (674)
Drug Delivery (2)
Drug Development (2511)
Employer Resources (2)
FDA (218)
Job Trends (277)
News (7723)
Policy (419)
Tag
2024 Bio NC Standard (1)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (2)
2024 Genetown Standard (1)
2024 Pharm Country Standard (1)
Academia (40)
Adcomms (3)
Allergies (4)
Alliances (1337)
ALS (1)
Alzheimer's disease (10)
Antibody-drug conjugate (ADC) (8)
Approvals (217)
Artificial intelligence (4)
Automation (1)
Bankruptcy (4)
Best Places to Work (221)
BIOSECURE Act (4)
Biosimilars (3)
Biotechnology (15)
Breast cancer (1)
Cancer (57)
Cardiovascular disease (6)
Career advice (10)
CAR-T (10)
Cell therapy (29)
Clinical research (1932)
Collaboration (29)
Compensation (14)
COVID-19 (104)
CRISPR (4)
C-suite (9)
Cystic fibrosis (1)
Data (47)
Diabetes (3)
Diagnostics (41)
Drug discovery (1)
Earnings (1458)
Editorial (1)
Employer resources (2)
Events (2491)
Executive appointments (33)
FDA (245)
Featured Employer (2)
Funding (28)
Gene editing (8)
Gene therapy (18)
GLP-1 (18)
Government (45)
Guidances (1)
Healthcare (399)
Immunology and inflammation (1)
Infectious disease (105)
Inflammatory bowel disease (6)
Intellectual property (3)
Interviews (3)
IPO (363)
Job creations (63)
Job search strategy (10)
Kidney cancer (1)
Labor market (2)
Layoffs (13)
Legal (67)
Liver cancer (1)
Lung cancer (7)
Lymphoma (10)
Management (1)
Manufacturing (9)
Medical device (71)
Medtech (71)
Mergers & acquisitions (324)
Metabolic disorders (6)
Neurodegenerative disease (4)
Neuroscience (17)
NextGen: Class of 2025 (140)
Non-profit (27)
Northern California (98)
Now hiring (1)
Obesity (3)
Opinion (1)
Ovarian cancer (1)
Pain (6)
Pancreatic cancer (1)
Parkinson's disease (2)
Patents (9)
Patient recruitment (3)
People (1781)
Phase I (870)
Phase II (931)
Phase III (562)
Pipeline (28)
Policy (6)
Postmarket research (25)
Preclinical (284)
Press Release (1)
Prostate cancer (2)
Radiopharmaceuticals (2)
Rare diseases (7)
Real estate (119)
Recruiting (1)
Regulatory (356)
Reports (2)
Research institute (65)
Resumes & cover letters (3)
RSV (1)
Schizophrenia (3)
Series A (8)
Series B (2)
Service/supplier (1)
Southern California (94)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (106)
Supply chain (1)
United States (617)
Vaccines (12)
Webinars (1)
Weight loss (1)
Date
Today (2)
Last 7 days (24)
Last 30 days (71)
Last 365 days (1039)
2025 (243)
2024 (1075)
2023 (1311)
2022 (1716)
2021 (1734)
2020 (1300)
2019 (775)
2018 (580)
2017 (705)
2016 (589)
2015 (675)
2014 (460)
2013 (376)
2012 (327)
2011 (328)
2010 (348)
Location
Africa (14)
Arizona (1)
Asia (1255)
Australia (97)
California (258)
Canada (70)
China (30)
Colorado (3)
Connecticut (7)
Delaware (5)
Europe (1544)
Florida (17)
Idaho (1)
Illinois (5)
India (2)
Indiana (1)
Japan (2)
Maryland (49)
Massachusetts (115)
Michigan (1)
Minnesota (6)
New Jersey (47)
New Mexico (1)
New York (21)
North Carolina (16)
Northern California (98)
Oklahoma (1)
Pennsylvania (43)
South America (9)
Southern California (94)
Texas (19)
Utah (1)
Washington D.C. (2)
Washington State (9)
Wisconsin (1)
13,992 Results for "biothera".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Bio-Thera and Dr. Reddy’s Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
March 28, 2025
·
8 min read
Press Releases
Bio-Thera Solutions Announces Regulatory Filing Acceptance for BAT2506, a Proposed Biosimilar to Simponi®, in the European Union
February 7, 2025
·
5 min read
Press Releases
Accord BioPharma Strengthens Pipeline Through Exclusive U.S. Licensing Agreement with Bio-Thera for BAT2506, a Proposed Golimumab Biosimilar
February 10, 2025
·
4 min read
Press Releases
Bio-Thera Solutions Expands Partnership with SteinCares in LATAM with Addition of a Third Biosimilar to Partnership
December 16, 2024
·
4 min read
Press Releases
Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of America
February 10, 2025
·
6 min read
Business
Bio-Thera Solutions Partners with SteinCares to Market Two Biosimilars in LATAM
Bio-Thera Solutions announced today a new licensing agreement for two biosimilars under which SteinCares will have exclusive rights to distribute and market Bio-Thera’s pharmaceuticals in Brazil and the rest of the region.
March 18, 2024
·
5 min read
Press Releases
Bio-Thera Solutions Partners with Tabuk Pharmaceuticals to Commercialize BAT2206, a Stelara® (Ustekinumab) Biosimilar in Saudi Arabia
December 24, 2024
·
6 min read
Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi® (bevacizumab), a Biosimilar Referencing Avastin®
Bio-Thera Solutions Inc., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for Avzivi®, a biosimilar monoclonal antibody referencing AVASTIN®.
June 3, 2024
·
5 min read
Business
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera Solutions (688177:SH) and global specialty, generic and consumer healthcare medicines company STADA Arzneimittel AG have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® (golimumab).
May 28, 2024
·
5 min read
Press Releases
Bio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorders
January 14, 2025
·
5 min read
1 of 1,400
Next
